Population as of 31 December 2018 | cases (N) | Prevalence | 95% CI | |
Overall | 5 819 388 | 749 | 12.9 | 11.9 to 13.8 |
By Sex* | ||||
Females | 2 922 867 | 337 | 11.4 | 10.2 to 12.6 |
Males | 2 896 521 | 412 | 14.3 | 12.9 to 15.7 |
By Age (years)† | ||||
≤12 | 823 126 | 84 | 10.1 | 8.0 to 12.3 |
13–18 | 408 755 | 26 | 6.4 | 3.9 to 8.8 |
19–24 | 461 023 | 25 | 5.4 | 3.3 to 7.5 |
25–34 | 748 530 | 40 | 5.3 | 3.7 to 7.0 |
35–44 | 708 488 | 85 | 12.0 | 9.4 to 14.5 |
45–54 | 812 438 | 137 | 16.8 | 14.0 to 19.6 |
55–64 | 720 665 | 149 | 20.7 | 17.4 to 24.0 |
≥65 | 1 136 363 | 203 | 17.9 | 15.4 to 20.3 |
By end of year†‡ | ||||
2004 | 5 489 869 | 63 | 1.1 | 0.8 to 1.4 |
2009 | 5 617 289 | 220 | 4.0 | 3.4 to 4.5 |
2014 | 5 728 373 | 468 | 8.2 | 7.5 to 8.9 |
2018 | 5 819 388 | 749 | 12.9 | 11.9 to 13.8 |
*Adjusted to the population age distribution as of 31 December 2018.
†Adjusted to the population sex distribution as of 31 December 2018.
‡Adjusted to the age and sex distribution as of 31 December 2018.
AATD, alpha-1 antitrypsin deficiency; dAATD, diagnosed alpha-1 antitrypsin deficiency.